Invivyd (NASDAQ:IVVD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Invivyd (NASDAQ:IVVD – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03, FiscalAI reports. The company had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.04 million. Invivyd had a negative net margin of 214.77% and a negative return on equity of 62.49%.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.51 on Wednesday. The firm has a market cap of $151.09 million, a price-to-earnings ratio of -1.39 and a beta of 1.20. The stock’s fifty day moving average price is $0.71 and its two-hundred day moving average price is $1.08. Invivyd has a one year low of $0.49 and a one year high of $3.01.

Analyst Ratings Changes

IVVD has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a report on Monday. Weiss Ratings raised shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a research report on Thursday, August 27th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Invivyd currently has an average rating of “Hold” and an average target price of $10.00.

Get Our Latest Report on Invivyd

Invivyd Company Profile

(Get Free Report)

Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.

Featured Stories

Earnings History for Invivyd (NASDAQ:IVVD)

Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.